Trial Profile
Phase II Trial of Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms CTLA-4 NY-ESO-1
- 11 Aug 2016 Status changed from active, no longer recruiting to completed.
- 09 Aug 2016 Trial was completed in Germany.
- 29 Jul 2015 Planned End Date changed from 1 Dec 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov.